NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104

NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104 – Phase 1 safety study of NTS-104 is initiated in healthy volunteers – Compound is being developed for stroke and other Central Nervous System (CNS) injuries ATLANTA, GA, June 1, 2023 – NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing neuroprotective therapeutics for treating patients with stroke and other CNS injuries, today announced that it has commenced dosing in a Phase 1 study of its investigational drug NTS-104, in healthy volunteers. The single-dose, randomized, double-blind, placebo-controlled, Phase 1 single-center dose-escalation study will assess the safety, tolerability, and pharmacokinetics of intravenous NTS-104 in healthy US participants. The study is expected to enroll a total of 32 participants across four cohorts. For more information, please visit www.clinicaltrials.gov . (NCT05547438) About NTS-104 NTS-104 is a novel, water-soluble neurosteroid prodrug that, when delivered intravenously, is converted in the bloodstream to NTS-105, the active neurosteroid. NTS-105 rapidly enters the brain at concentrations sufficient to modulate key target receptors, protecting neurons from inflammation, edema, and programmed cell death. NTS-104 has demonstrated efficacy in multiple preclinical brain injury models validated at independent laboratories. NeuroTrauma Sciences plans to conduct a Phase 2 study of NTS-104 in acute ischemic stroke. About NeuroTrauma Sciences NeuroTrauma Sciences is a biopharmaceutical company advancing its mission to develop neuroprotective therapies for treating patients with stroke and other CNS injuries. By leveraging insights into the biology of CNS injury, NTS is advancing a pipeline of therapeutic candidates targeting ischemic stroke and CNS injuries. For additional information, please visit www.neurotraumasciences.com . Contacts: NeuroTrauma Sciences William Fricker, CPA, MBA Chief Financial Officer M: 215-622-7875 [email protected] SMP Communications Susan Pietropaolo M: 201-923-2049 [email protected]

The release as fetched from its publisher. neurotraumasciences.com ↗